MCID: END041
MIFTS: 60

Endometrial Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Endometrial Adenocarcinoma

MalaCards integrated aliases for Endometrial Adenocarcinoma:

Name: Endometrial Adenocarcinoma 12 15 74
Endometrial Endometrioid Adenocarcinoma 12 17 74
Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation 6 17
Endometrial Adenoacanthoma 12 74
Endometrial Endometrioid Adenocarcinoma with Squamous Differentiation 12
Endometrioid Carcinoma of Endometrium 12
Endometrioid Adenomas and Carcinomas 12
Adenocarcinoma of the Endometrium 12
Endometrioid Adenoma or Carcinoma 12
Adenocarcinoma of Endometrium 12
Endometrium Adenocarcinoma 17
Adenocarcinoma of Uterus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2870

Summaries for Endometrial Adenocarcinoma

Disease Ontology : 12 An endometrial carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Endometrial Adenocarcinoma, also known as endometrial endometrioid adenocarcinoma, is related to endometrial clear cell adenocarcinoma and endometrial mucinous adenocarcinoma. An important gene associated with Endometrial Adenocarcinoma is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are ERK Signaling and Gene Expression. The drugs Bupivacaine and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and lymph node, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435)

Related Diseases for Endometrial Adenocarcinoma

Diseases related to Endometrial Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 320)
# Related Disease Score Top Affiliating Genes
1 endometrial clear cell adenocarcinoma 32.6 CTSD ESR1
2 endometrial mucinous adenocarcinoma 32.3 CDKN2A ESR1 MKI67 PGR
3 adenomyosis 31.2 ESR1 PGR VEGFA
4 mucinous adenocarcinoma 31.1 CDKN2A KRAS KRT7 MLH1
5 papillary serous adenocarcinoma 30.9 KRT7 PGR TP53
6 adenocarcinoma 30.8 AKT1 CDKN2A ERBB2 FGFR2 KRAS MALAT1
7 cervical squamous cell carcinoma 30.7 CDKN2A MKI67 TP53
8 adenocarcinoma in situ 30.7 CDKN2A KRAS KRT7
9 endometriosis 30.6 ESR1 ESR2 PGR PTEN VEGFA
10 carcinosarcoma 30.4 ERBB2 KRAS KRT7 PGR PTEN TP53
11 adenosarcoma 30.3 ESR1 MKI67 PGR TP53
12 papilloma 30.2 CDKN2A KRT7 PTEN TP53
13 papillary adenocarcinoma 30.2 ERBB2 KRT7 PGR TP53
14 leiomyoma 30.1 ESR1 ESR2 MKI67 PGR
15 endometriosis of ovary 30.0 ESR1 ESR2 PGR
16 cervical adenocarcinoma 30.0 CDKN2A ERBB2 ESR1 KRT7 PGR TP53
17 wilms tumor 1 29.9 ERBB2 ESR1 KRT7 PGR TP53
18 gastrointestinal stromal tumor 29.8 AKT1 CDKN2A KRAS MKI67 PTEN TP53
19 ovarian disease 29.8 AKT1 ESR1 ESR2 PGR PTEN TP53
20 hemangioma 29.6 FGF2 KRAS PTEN VEGFA
21 endometrial stromal sarcoma 29.6 ESR1 MALAT1 PGR TP53
22 squamous cell carcinoma 29.0 AKT1 CDKN2A ERBB2 FGFR2 MALAT1 MKI67
23 lung cancer susceptibility 3 28.7 AKT1 CDKN2A ERBB2 ESR2 KRAS KRT7
24 endometrial cancer 28.6 AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
25 colorectal cancer 28.1 AKT1 CDKN2A CTSD ERBB2 ESR2 KRAS
26 breast cancer 27.6 AKT1 CTSD ERBB2 ESR1 ESR2 FGF2
27 villoglandular endometrial endometrioid adenocarcinoma 11.2
28 oxyphilic endometrial endometrioid adenocarcinoma 11.2
29 secretory uterine corpus endometrioid adenocarcinoma 11.2
30 mucin-rich endometrial endometrioid adenocarcinoma 11.2
31 sarcomatoid uterine corpus endometrioid adenocarcinoma 11.2
32 endometrial mixed adenocarcinoma 11.2
33 vestibular gland benign neoplasm 10.6 ESR1 PGR
34 vulvar benign neoplasm 10.6 ESR1 PGR
35 trigonitis 10.6 ESR1 PGR
36 vulvar syringoma 10.6 ESR1 PGR
37 lung leiomyoma 10.6 ESR1 PGR
38 vulvar leiomyoma 10.6 ESR1 PGR
39 bartholin's gland adenoma 10.6 ESR1 PGR
40 vulvar dystrophy 10.6 CDKN2A PGR
41 predominantly cortical thymoma 10.6 ESR1 PGR
42 breast duct papilloma 10.6 PGR PTEN
43 endometrium carcinoma in situ 10.6 PGR TP53
44 bizarre leiomyoma 10.6 CDKN2A PGR
45 bladder squamous cell carcinoma 10.6 CDKN2A TP53
46 infiltrating angiolipoma 10.6 CDKN2A VEGFA
47 mucinous stomach adenocarcinoma 10.6 PTEN VEGFA
48 endosalpingiosis 10.6 KRT7 PGR
49 mucinous adenofibroma 10.6 ESR1 KRT7
50 hyperplastic polyposis syndrome 10.6 KRAS TP53

Graphical network of the top 20 diseases related to Endometrial Adenocarcinoma:



Diseases related to Endometrial Adenocarcinoma

Symptoms & Phenotypes for Endometrial Adenocarcinoma

GenomeRNAi Phenotypes related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 CTSD ERBB2 FGFR2 PTEN VEGFA
2 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 ESR1 ESR2 MKI67 PTEN

MGI Mouse Phenotypes related to Endometrial Adenocarcinoma:

47 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.5 AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
2 cellular MP:0005384 10.49 AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
3 behavior/neurological MP:0005386 10.47 AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
4 cardiovascular system MP:0005385 10.44 AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
5 endocrine/exocrine gland MP:0005379 10.41 AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
6 growth/size/body region MP:0005378 10.4 AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
7 hematopoietic system MP:0005397 10.39 AKT1 CDKN2A CTSD ESR1 ESR2 FGF2
8 immune system MP:0005387 10.37 AKT1 CDKN2A CTSD ESR1 ESR2 FGFR2
9 integument MP:0010771 10.36 AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
10 mortality/aging MP:0010768 10.36 AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
11 digestive/alimentary MP:0005381 10.35 CDKN2A CTSD ERBB2 ESR1 ESR2 FGFR2
12 embryo MP:0005380 10.3 AKT1 CDKN2A ERBB2 ESR1 FGFR2 KRAS
13 neoplasm MP:0002006 10.29 AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
14 muscle MP:0005369 10.27 AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
15 nervous system MP:0003631 10.23 AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
16 limbs/digits/tail MP:0005371 10.19 ERBB2 ESR1 ESR2 FGFR2 KRAS PGR
17 adipose tissue MP:0005375 10.18 AKT1 ESR1 ESR2 FGFR2 LNPEP PTEN
18 liver/biliary system MP:0005370 10.18 AKT1 CDKN2A ESR1 ESR2 FGFR2 KRAS
19 normal MP:0002873 10.14 AKT1 ERBB2 ESR1 ESR2 FGFR2 KRAS
20 no phenotypic analysis MP:0003012 10.13 CDKN2A ESR1 ESR2 FGFR2 KRAS LNPEP
21 reproductive system MP:0005389 10.07 AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
22 hearing/vestibular/ear MP:0005377 10.06 CTSD ESR2 FGF2 FGFR2 KRAS TP53
23 renal/urinary system MP:0005367 9.92 ESR1 ESR2 FGFR2 KRAS KRT7 PTEN
24 respiratory system MP:0005388 9.9 AKT1 CDKN2A ERBB2 ESR1 ESR2 FGFR2
25 pigmentation MP:0001186 9.77 CDKN2A FGFR2 KRAS PTEN TP53
26 skeleton MP:0005390 9.73 AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
27 vision/eye MP:0005391 9.28 CDKN2A CTSD FGF2 FGFR2 KRAS MLH1

Drugs & Therapeutics for Endometrial Adenocarcinoma

Drugs for Endometrial Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
2
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
4 Anesthetics, General Phase 4
5 Hypnotics and Sedatives Phase 4
6 Adrenergic alpha-Agonists Phase 4
7 Excitatory Amino Acids Phase 4
8 Adrenergic Agonists Phase 4
9 Adrenergic Agents Phase 4
10 Central Nervous System Depressants Phase 4
11 Analgesics Phase 4
12 Anesthetics Phase 4
13 Adrenergic alpha-2 Receptor Agonists Phase 4
14 Excitatory Amino Acid Antagonists Phase 4
15 Neurotransmitter Agents Phase 4
16 Anesthetics, Dissociative Phase 4
17 Anesthetics, Intravenous Phase 4
18 Peripheral Nervous System Agents Phase 4
19 Analgesics, Non-Narcotic Phase 4
20 Anesthetics, Local Phase 4
21
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
22
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 38904 498142
23
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
24
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
25
Lenograstim Approved, Investigational Phase 3 135968-09-1
26
Epirubicin Approved Phase 3 56420-45-2 41867
27
Metformin Approved Phase 2, Phase 3,Early Phase 1,Not Applicable 657-24-9 14219 4091
28
Pembrolizumab Approved Phase 3,Phase 2 1374853-91-4
29
Doxil Approved June 1999 Phase 3,Phase 1 31703
30 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
31 Antimitotic Agents Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
33 Hormones Phase 3,Phase 2,Phase 1
34 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
35 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
36 Topoisomerase Inhibitors Phase 3,Phase 1
37 Adjuvants, Immunologic Phase 3
38 Immunologic Factors Phase 3,Phase 2,Phase 1
39 Hypoglycemic Agents Phase 2, Phase 3,Early Phase 1,Not Applicable
40 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
42 Estrogens Phase 3,Phase 2,Phase 1
43 Hormone Antagonists Phase 3,Phase 2,Phase 1
44 Estrogens, Conjugated (USP) Phase 3
45
Medroxyprogesterone acetate Approved, Investigational Phase 2 71-58-9
46
Levonorgestrel Approved, Investigational Phase 2,Not Applicable 797-63-7, 17489-40-6 13109
47
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
48
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
49
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
50
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines Completed NCT03164590 Phase 4 Ketamine;dexmedetomidine;bupivacaine
2 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
6 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
7 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
8 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
9 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
10 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
11 Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Not yet recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
12 Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer Terminated NCT00002976 Phase 3 conjugated estrogens
13 The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy Unknown status NCT02335203 Phase 2 Depot medroxyprogesterone acetate
14 Treatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer Unknown status NCT01594879 Phase 2
15 Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer Unknown status NCT01041027 Phase 2 Paclitaxel;Carboplatin
16 Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma Completed NCT01968317 Phase 2 Megestrol acetate and metformin;Megestrol acetate
17 A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women Completed NCT01877564 Phase 2 Metformin
18 A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation Completed NCT00285415 Phase 2 Docetaxel and Carboplatin
19 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
20 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
21 Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00095979 Phase 2 ixabepilone
22 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
23 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
24 Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer Completed NCT00870337 Phase 2 everolimus
25 Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Completed NCT00006089 Phase 2
26 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
27 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
28 Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT00087100 Phase 2 pemetrexed disodium
29 Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer Completed NCT00004251 Phase 2 letrozole
30 Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer Completed NCT00030485 Phase 2 erlotinib hydrochloride
31 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
32 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
33 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
34 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
35 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
36 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
37 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
38 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
39 Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery Completed NCT00331760 Phase 2 cisplatin
40 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed NCT02923349 Phase 1, Phase 2 INCAGN01949
41 Pembro/Carbo/Taxol in Endometrial Cancer Recruiting NCT02549209 Phase 2 Pembrolizumab;Paclitaxel;Carboplatin
42 Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer Recruiting NCT03643510 Phase 2 Fulvestrant;Abemaciclib
43 Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer Recruiting NCT03348631 Phase 2 Tazemetostat
44 Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) Recruiting NCT02730923 Phase 1, Phase 2 AZD2014;Anastrozole
45 Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer Recruiting NCT02730429 Phase 2 Palbociclib/placebo;Letrozole
46 Improving the Treatment for Women With Early Stage Cancer of the Uterus Recruiting NCT01686126 Phase 2 Levonorgestrel;Metformin
47 Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting NCT00492778 Phase 2 Cisplatin
48 An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Recruiting NCT02697591 Phase 1, Phase 2 INCAGN01876
49 Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06 Recruiting NCT01164150 Phase 2
50 Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer Recruiting NCT02397083 Phase 2 Everolimus

Search NIH Clinical Center for Endometrial Adenocarcinoma

Genetic Tests for Endometrial Adenocarcinoma

Anatomical Context for Endometrial Adenocarcinoma

MalaCards organs/tissues related to Endometrial Adenocarcinoma:

42
Uterus, Ovary, Lymph Node, Bone, Cervix, Endothelial, Testes

Publications for Endometrial Adenocarcinoma

Articles related to Endometrial Adenocarcinoma:

(show top 50) (show all 1086)
# Title Authors Year
1
Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma. ( 31077193 )
2019
2
A case of incidental endometrial adenocarcinoma diagnosed in early pregnancy and managed conservatively. ( 30993161 )
2019
3
Oocyte collection and in vitro maturation after train transportation of human follicular fluid aspirated from resected non-stimulated ovaries of patients with endometrial adenocarcinoma. ( 30996682 )
2019
4
Expression of polymeric immunoglobulin receptor and its biological function in endometrial adenocarcinoma. ( 30964121 )
2019
5
Gprotein-coupled estrogen receptor 30 and extracellular signal-regulated kinase 1/2 in endometrial adenocarcinoma. ( 30915827 )
2019
6
PGK1 facilities cisplatin chemoresistance by triggering HSP90/ERK pathway mediated DNA repair and methylation in endometrial endometrioid adenocarcinoma. ( 30925862 )
2019
7
Peri-Ampullary Metastasis From Endometrial Adenocarcinoma: A Rare Etiology of Obstructive Jaundice. ( 30834033 )
2019
8
A tumor board report of an 83-year-old woman with stage IB grade 3 endometrioid endometrial adenocarcinoma. ( 30770127 )
2019
9
Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression. ( 30789355 )
2019
10
Expression and role of hScrib in endometrium, endometriosis, and endometrial adenocarcinoma. ( 30702562 )
2019
11
RRBP1 overexpression is associated with progression and prognosis in endometrial endometrioid adenocarcinoma. ( 30684972 )
2019
12
L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB. ( 30591489 )
2019
13
The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification. ( 30479097 )
2019
14
Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma. ( 29210800 )
2019
15
Remarkable response of recurrent endometrial adenocarcinoma to daily oral administration of half-dose etoposide. ( 30788108 )
2018
16
Isolated Gastric Metastasis of Endometrial Adenocarcinoma: First Case Report and Review of Pertinent Literature. ( 30627266 )
2018
17
The miR-503 cluster is coordinately under-expressed in endometrial endometrioid adenocarcinoma and targets many oncogenes, cell cycle genes, DNA repair genes and chemotherapy response genes. ( 30425513 )
2018
18
BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway. ( 30445932 )
2018
19
Diagnostic Value of Assessment of Cervical Involvement in Early-Stage Endometrial Adenocarcinoma: Comparison of Magnetic Resonance Imaging (MRI) Versus Hysteroscopy. ( 30398217 )
2018
20
The cigarette smoke components induced the cell proliferation and epithelial to mesenchymal transition via production of reactive oxygen species in endometrial adenocarcinoma cells. ( 30236600 )
2018
21
Role of Morphometry and Matrix Metalloproteinase-9 Expression in Differentiating between Atypical Endometrial Hyperplasia and Low Grade Endometrial Adenocarcinoma ( 30139240 )
2018
22
Endometrial Adenocarcinoma, Endometrioid Type. ( 29976383 )
2018
23
Overexpression of HOMER2 predicts better outcome in low-grade endometrioid endometrial adenocarcinoma. ( 29891190 )
2018
24
Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease. ( 29898896 )
2018
25
Disparate genomic characteristics of concurrent endometrial adenocarcinoma and ovarian granulosa cell tumor, revealed by targeted next-generation sequencing. ( 29937308 )
2018
26
Synchronous endometrial adenocarcinoma and carcinosarcoma in endometrial polyp. ( 29854405 )
2018
27
Stage I and II Endometrial Adenocarcinoma: Analysis of 2009 FIGO Staging Revision and Impact on Survival by Adjuvant Therapy. ( 26886945 )
2018
28
Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations. ( 28819700 )
2018
29
The importance of hCG in human endometrial adenocarcinoma and breast cancer. ( 28967068 )
2018
30
Amide Proton Transfer MR Imaging of Endometrioid Endometrial Adenocarcinoma: Association with Histologic Grade. ( 29083987 )
2018
31
Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair. ( 29084048 )
2018
32
Robotic Splenectomy for Isolated Splenic Recurrence of Endometrial Adenocarcinoma. ( 29128439 )
2018
33
Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma. ( 29243125 )
2018
34
Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis. ( 29266019 )
2018
35
Gastric-Type Endometrial Adenocarcinoma: Report of Two Cases in Patients From the United States. ( 29281925 )
2018
36
Pathological and molecular diagnosis of bilateral inguinal lymph nodes metastases from low-grade endometrial adenocarcinoma: a case report with review of the literature. ( 29295713 )
2018
37
Endometrial Adenocarcinoma With Pulmonary Recurrence. ( 29326341 )
2018
38
LRIG2 is a growth suppressor of Hec-1A and Ishikawa endometrial adenocarcinoma cells by regulating PI3K/AKT- and EGFR-mediated apoptosis and cell-cycle. ( 29358688 )
2018
39
Patterns of Recurrence, Long-term Survival and Toxicity Analysis of Endometrial Adenocarcinoma Patients Reclassified Under the Recent ESMO-ESGO-ESTRO Stratification: Seven-Year Results From a Single Institution. ( 29683879 )
2018
40
Malignant changes in adenomyosis in patients with endometrial adenocarcinoma: A case series. ( 29069006 )
2017
41
Normal endometrial stromal cells regulate 17β-estradiol-induced epithelial-mesenchymal transition via slug and E-cadherin in endometrial adenocarcinoma cells in vitro. ( 27449470 )
2017
42
Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines. ( 27585662 )
2017
43
Post hysterectomy occurrence of endometrial adenocarcinoma in association with granulosa cell tumour: a case report. ( 27922275 )
2017
44
Enhanced expression of hydroxylated ceramide in well-differentiated endometrial adenocarcinoma. ( 28123520 )
2017
45
Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series. ( 28128512 )
2017
46
Impact of Conservative Managements in Young Women With Grade 2 or 3 Endometrial Adenocarcinoma Confined to the Endometrium. ( 28187090 )
2017
47
Deep Infiltrating Endometriosis and Endometrial Adenocarcinoma Express High Levels of Myostatin and Its Receptors Messenger RNAs. ( 28345488 )
2017
48
Sentinel lymph node mapping reduces practice pattern variations in surgical staging for endometrial adenocarcinoma: A before and after study. ( 28363672 )
2017
49
Curcumin exhibits anti-tumor effect and attenuates cellular migration via Slit-2 mediated down-regulation of SDF-1 and CXCR4 in endometrial adenocarcinoma cells. ( 28402926 )
2017
50
Endometrioid endometrial adenocarcinoma: an increase of G3 cancers? ( 28421274 )
2017

Variations for Endometrial Adenocarcinoma

ClinVar genetic disease variations for Endometrial Adenocarcinoma:

6 (show all 36)
# Gene Variation Type Significance SNP ID Assembly Location
1 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
2 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh38 Chromosome 10, 121520163: 121520163
3 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
4 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214
5 FGFR2 NM_000141.4(FGFR2): c.1694A> G (p.Glu565Gly) single nucleotide variant Likely pathogenic rs121918506 GRCh37 Chromosome 10, 123256215: 123256215
6 FGFR2 NM_000141.4(FGFR2): c.1694A> G (p.Glu565Gly) single nucleotide variant Likely pathogenic rs121918506 GRCh38 Chromosome 10, 121496701: 121496701
7 FGFR2 NM_000141.4(FGFR2): c.1645A> C (p.Asn549His) single nucleotide variant Likely pathogenic rs1057519045 GRCh37 Chromosome 10, 123258036: 123258036
8 FGFR2 NM_000141.4(FGFR2): c.1645A> C (p.Asn549His) single nucleotide variant Likely pathogenic rs1057519045 GRCh38 Chromosome 10, 121498522: 121498522
9 EGFR NM_005228.4(EGFR): c.2068G> A (p.Glu690Lys) single nucleotide variant Likely pathogenic rs1057519794 GRCh37 Chromosome 7, 55241620: 55241620
10 EGFR NM_005228.4(EGFR): c.2068G> A (p.Glu690Lys) single nucleotide variant Likely pathogenic rs1057519794 GRCh38 Chromosome 7, 55173927: 55173927
11 FGFR2 NM_022970.3(FGFR2): c.1978A> G (p.Lys660Glu) single nucleotide variant Likely pathogenic rs1057519795 GRCh37 Chromosome 10, 123247516: 123247516
12 FGFR2 NM_022970.3(FGFR2): c.1978A> G (p.Lys660Glu) single nucleotide variant Likely pathogenic rs1057519795 GRCh38 Chromosome 10, 121488002: 121488002
13 FGFR2 NM_000141.4(FGFR2): c.1849T> A (p.Leu617Met) single nucleotide variant Likely pathogenic rs1057519796 GRCh37 Chromosome 10, 123256060: 123256060
14 FGFR2 NM_000141.4(FGFR2): c.1849T> A (p.Leu617Met) single nucleotide variant Likely pathogenic rs1057519796 GRCh38 Chromosome 10, 121496546: 121496546
15 FGFR2 NM_000141.4(FGFR2): c.1690G> A (p.Val564Ile) single nucleotide variant Likely pathogenic rs1057519797 GRCh37 Chromosome 10, 123256219: 123256219
16 FGFR2 NM_000141.4(FGFR2): c.1690G> A (p.Val564Ile) single nucleotide variant Likely pathogenic rs1057519797 GRCh38 Chromosome 10, 121496705: 121496705
17 FGFR2 NM_022970.3(FGFR2): c.1650T> G (p.Asn550Lys) single nucleotide variant Likely pathogenic rs121913476 GRCh37 Chromosome 10, 123258034: 123258034
18 FGFR2 NM_022970.3(FGFR2): c.1650T> G (p.Asn550Lys) single nucleotide variant Likely pathogenic rs121913476 GRCh38 Chromosome 10, 121498520: 121498520
19 FGFR2 NM_000141.4(FGFR2): c.1647T> A (p.Asn549Lys) single nucleotide variant Likely pathogenic rs121913476 GRCh37 Chromosome 10, 123258034: 123258034
20 FGFR2 NM_000141.4(FGFR2): c.1647T> A (p.Asn549Lys) single nucleotide variant Likely pathogenic rs121913476 GRCh38 Chromosome 10, 121498520: 121498520
21 FGFR2 NM_000141.4(FGFR2): c.1639A> G (p.Ile547Val) single nucleotide variant Likely pathogenic rs1057519798 GRCh37 Chromosome 10, 123258042: 123258042
22 FGFR2 NM_000141.4(FGFR2): c.1639A> G (p.Ile547Val) single nucleotide variant Likely pathogenic rs1057519798 GRCh38 Chromosome 10, 121498528: 121498528
23 FGFR2 NM_022970.3(FGFR2): c.1614G> T (p.Met538Ile) single nucleotide variant Likely pathogenic rs1057519799 GRCh37 Chromosome 10, 123258070: 123258070
24 FGFR2 NM_022970.3(FGFR2): c.1614G> T (p.Met538Ile) single nucleotide variant Likely pathogenic rs1057519799 GRCh38 Chromosome 10, 121498556: 121498556
25 FGFR2 NM_022970.3(FGFR2): c.1614G> C (p.Met538Ile) single nucleotide variant Likely pathogenic rs1057519799 GRCh37 Chromosome 10, 123258070: 123258070
26 FGFR2 NM_022970.3(FGFR2): c.1614G> C (p.Met538Ile) single nucleotide variant Likely pathogenic rs1057519799 GRCh38 Chromosome 10, 121498556: 121498556
27 FGFR2 NM_000141.4(FGFR2): c.1611G> A (p.Met537Ile) single nucleotide variant Likely pathogenic rs1057519799 GRCh37 Chromosome 10, 123258070: 123258070
28 FGFR2 NM_000141.4(FGFR2): c.1611G> A (p.Met537Ile) single nucleotide variant Likely pathogenic rs1057519799 GRCh38 Chromosome 10, 121498556: 121498556
29 FGFR2 NM_000141.4(FGFR2): c.1605G> T (p.Met535Ile) single nucleotide variant Likely pathogenic rs1057519800 GRCh37 Chromosome 10, 123258076: 123258076
30 FGFR2 NM_000141.4(FGFR2): c.1605G> T (p.Met535Ile) single nucleotide variant Likely pathogenic rs1057519800 GRCh38 Chromosome 10, 121498562: 121498562
31 FGFR2 NM_022970.3(FGFR2): c.1608G> C (p.Met536Ile) single nucleotide variant Likely pathogenic rs1057519800 GRCh37 Chromosome 10, 123258076: 123258076
32 FGFR2 NM_022970.3(FGFR2): c.1608G> C (p.Met536Ile) single nucleotide variant Likely pathogenic rs1057519800 GRCh38 Chromosome 10, 121498562: 121498562
33 FGFR2 NM_022970.3(FGFR2): c.1608G> A (p.Met536Ile) single nucleotide variant Likely pathogenic rs1057519800 GRCh37 Chromosome 10, 123258076: 123258076
34 FGFR2 NM_022970.3(FGFR2): c.1608G> A (p.Met536Ile) single nucleotide variant Likely pathogenic rs1057519800 GRCh38 Chromosome 10, 121498562: 121498562
35 PIK3R2 NM_005027.3(PIK3R2): c.1681A> G (p.Asn561Asp) single nucleotide variant Likely pathogenic rs1057519801 GRCh37 Chromosome 19, 18278061: 18278061
36 PIK3R2 NM_005027.3(PIK3R2): c.1681A> G (p.Asn561Asp) single nucleotide variant Likely pathogenic rs1057519801 GRCh38 Chromosome 19, 18167251: 18167251

Cosmic variations for Endometrial Adenocarcinoma:

9 (show top 50) (show all 4244)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6935601 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.1124G>T p.S375I 23:15822917-15822917 0
2 COSM6982868 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.854C>A p.S285Y 23:15820233-15820233 0
3 COSM6935600 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.514T>A p.C172S 23:15809275-15809275 0
4 COSM6845183 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2143C>T p.R715* 16:72958003-72958003 0
5 COSM6845146 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8961G>T p.K2987N 16:72793721-72793721 0
6 COSM6845174 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4129C>A p.L1377I 16:72798553-72798553 0
7 COSM973503 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8152G>A p.A2718T 16:72794530-72794530 0
8 COSM6845142 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3504G>T p.E1168D 16:72829804-72829804 0
9 COSM6845190 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9555A>C p.Q3185H 16:72788721-72788721 0
10 COSM1709385 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3925C>T p.R1309* 16:72800069-72800069 0
11 COSM6845133 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2740G>A p.D914N 16:72950945-72950945 0
12 COSM6845164 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7666G>C p.A2556P 16:72795016-72795016 0
13 COSM6845182 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3628C>T p.R1210* 16:72811940-72811940 0
14 COSM6845156 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2875G>A p.D959N 16:72950810-72950810 0
15 COSM973493 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9001G>T p.E3001* 16:72793681-72793681 0
16 COSM6826430 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8002C>T p.R2668* 16:72794680-72794680 0
17 COSM6845155 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2725G>A p.G909S 16:72950960-72950960 0
18 COSM1233352 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6446G>A p.R2149H 16:72796236-72796236 0
19 COSM6826396 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.568G>A p.V190M 16:72959578-72959578 0
20 COSM6845159 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3829G>A p.V1277M 16:72811612-72811612 0
21 COSM5563443 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6820C>T p.Q2274* 16:72795862-72795862 0
22 COSM6845186 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9266A>C p.E3089A 16:72793416-72793416 0
23 COSM6984593 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6046G>A p.E2016K 16:72796636-72796636 0
24 COSM973492 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9006G>T p.K3002N 16:72793676-72793676 0
25 COSM6984595 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5623G>A p.E1875K 16:72797059-72797059 0
26 COSM973535 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4316G>A p.R1439Q 16:72798366-72798366 0
27 COSM6845141 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1969G>A p.G657S 16:72958177-72958177 0
28 COSM6845171 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3115C>T p.H1039Y 16:72950570-72950570 0
29 COSM6845173 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3863C>T p.T1288M 16:72811578-72811578 0
30 COSM6982810 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4103A>G p.N1368S 16:72798579-72798579 0
31 COSM1640552 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8849G>A p.R2950H 16:72793833-72793833 0
32 COSM6982809 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4406C>T p.A1469V 16:72798276-72798276 0
33 COSM6984596 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1378G>A p.E460K 16:72958768-72958768 0
34 COSM6845169 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5125G>T p.E1709* 16:72797557-72797557 0
35 COSM6845189 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8228A>G p.Y2743C 16:72794454-72794454 0
36 COSM1379731 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.884G>A p.R295H 16:72959262-72959262 0
37 COSM3276890 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3397G>A p.E1133K 16:72889782-72889782 0
38 COSM3276999 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.359G>A p.G120E 16:72959787-72959787 0
39 COSM6845185 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5635A>T p.K1879* 16:72797047-72797047 0
40 COSM6845129 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7559T>C p.L2520P 16:72795123-72795123 0
41 COSM6845179 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8576C>T p.T2859M 16:72794106-72794106 0
42 COSM973560 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1115G>A p.R372Q 16:72959031-72959031 0
43 COSM6845161 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5754G>T p.K1918N 16:72796928-72796928 0
44 COSM6845178 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8197C>A p.R2733S 16:72794485-72794485 0
45 COSM6845165 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8078G>A p.R2693Q 16:72794604-72794604 0
46 COSM6845188 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6058A>G p.K2020E 16:72796624-72796624 0
47 COSM6984594 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5941G>A p.E1981K 16:72796741-72796741 0
48 COSM6845127 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4274T>C p.I1425T 16:72798408-72798408 0
49 COSM973483 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.10750G>A p.A3584T 16:72787526-72787526 0
50 COSM6845170 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.338C>T p.A113V 16:72959808-72959808 0

Expression for Endometrial Adenocarcinoma

Search GEO for disease gene expression data for Endometrial Adenocarcinoma.

Pathways for Endometrial Adenocarcinoma

Pathways related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
2
Show member pathways
13.86 AKT1 CDKN2A ERBB2 ESR1 ESR2 MLH1
3
Show member pathways
13.77 AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
4
Show member pathways
13.47 AKT1 CTSD ERBB2 FGF2 FGFR2 KRAS
5
Show member pathways
13.4 AKT1 ERBB2 FGF2 FGFR2 KRAS TP53
6
Show member pathways
13.31 AKT1 ERBB2 ESR1 ESR2 FGF2 FGFR2
7
Show member pathways
13.11 AKT1 FGF2 FGFR2 KRAS PTEN TP53
8
Show member pathways
13.07 AKT1 CTSD ESR1 ESR2 KRAS PGR
9
Show member pathways
13 AKT1 CDKN2A FGF2 KRAS PTEN TP53
10
Show member pathways
13 AKT1 ERBB2 FGF2 FGFR2 KRAS PTEN
11
Show member pathways
12.84 AKT1 CDKN2A CTSD KRAS TP53
12 12.81 AKT1 ERBB2 FGF2 FGFR2 KRAS TP53
13
Show member pathways
12.77 AKT1 FGF2 FGFR2 KRAS VEGFA
14
Show member pathways
12.77 AKT1 CDKN2A ERBB2 FGFR2 KRAS MLH1
15
Show member pathways
12.74 AKT1 ERBB2 ESR1 KRAS PTEN TP53
16
Show member pathways
12.74 AKT1 ERBB2 FGF2 FGFR2 KRAS PTEN
17
Show member pathways
12.64 AKT1 ERBB2 FGF2 KRAS TP53
18
Show member pathways
12.64 AKT1 ERBB2 KRAS TP53 VEGFA
19 12.56 CDKN2A ERBB2 KRAS PTEN TP53 VEGFA
20
Show member pathways
12.55 AKT1 ERBB2 FGFR2 KRAS PTEN TP53
21
Show member pathways
12.49 AKT1 ERBB2 FGFR2 KRAS TP53
22
Show member pathways
12.49 AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
23 12.46 AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
24
Show member pathways
12.43 AKT1 ESR1 KRAS VEGFA
25
Show member pathways
12.43 AKT1 CTSD ERBB2 ESR1 ESR2 KRAS
26 12.39 AKT1 CDKN2A KRAS TP53
27
Show member pathways
12.36 AKT1 ERBB2 ESR1 ESR2
28
Show member pathways
12.32 AKT1 FGF2 FGFR2 KRAS TP53
29
Show member pathways
12.29 AKT1 KRAS TP53 VEGFA
30
Show member pathways
12.25 AKT1 ERBB2 FGFR2 KRAS PTEN TP53
31 12.24 AKT1 ERBB2 KRAS PTEN
32 12.24 AKT1 KRAS MLH1 TP53 VEGFA
33
Show member pathways
12.24 AKT1 FGF2 FGFR2 KRAS PTEN VEGFA
34 12.22 AKT1 CDKN2A KRAS PTEN TP53
35
Show member pathways
12.19 AKT1 ERBB2 KRAS PTEN
36 12.17 AKT1 ERBB2 FGFR2 KRAS PTEN TP53
37 12.17 AKT1 ERBB2 ESR1 FGF2 KRAS TP53
38 12.15 AKT1 FGF2 FGFR2 KRAS
39 12.12 CTSD MLH1 PTEN TP53
40 12.12 AKT1 ESR1 KRAS PTEN TP53 VEGFA
41 12.1 AKT1 CTSD KRAS PTEN
42
Show member pathways
12.07 AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
43 12.05 AKT1 ESR1 KRAS TP53
44 12.05 AKT1 CTSD KRAS PTEN TP53
45 12.03 AKT1 FGF2 TP53 VEGFA
46
Show member pathways
12 ERBB2 ESR1 KRAS PGR
47 11.99 AKT1 CDKN2A KRAS PTEN TP53
48 11.94 AKT1 CDKN2A ERBB2 KRAS PTEN TP53
49 11.93 AKT1 ESR1 ESR2 KRAS
50
Show member pathways
11.88 ESR1 ESR2 PGR

GO Terms for Endometrial Adenocarcinoma

Cellular components related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2

Biological processes related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.99 AKT1 ERBB2 MKI67 PTEN TP53
2 negative regulation of gene expression GO:0010629 9.97 AKT1 ESR1 PGR VEGFA
3 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 AKT1 CDKN2A ESR1 FGF2 FGFR2 PGR
4 angiogenesis GO:0001525 9.95 FGF2 FGFR2 PTEN VEGFA
5 positive regulation of cell proliferation GO:0008284 9.95 AKT1 FGF2 FGFR2 KRAS PTEN VEGFA
6 cell-cell signaling GO:0007267 9.94 ESR2 FGFR2 LNPEP PGR
7 MAPK cascade GO:0000165 9.93 ERBB2 FGF2 FGFR2 KRAS
8 positive regulation of protein phosphorylation GO:0001934 9.91 AKT1 ERBB2 KRAS VEGFA
9 positive regulation of protein kinase B signaling GO:0051897 9.88 ERBB2 ESR1 FGF2 FGFR2
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 FGF2 FGFR2 PTEN
11 cytokine-mediated signaling pathway GO:0019221 9.83 AKT1 FGF2 KRAS TP53 VEGFA
12 regulation of protein stability GO:0031647 9.81 CDKN2A KRAS PTEN
13 negative regulation of apoptotic process GO:0043066 9.81 AKT1 PTEN TP53 VEGFA
14 positive regulation of endothelial cell proliferation GO:0001938 9.8 AKT1 FGF2 VEGFA
15 positive regulation of epithelial cell proliferation GO:0050679 9.8 ERBB2 FGFR2 VEGFA
16 protein catabolic process GO:0030163 9.75 AKT1 CTSD LNPEP
17 positive regulation of blood vessel endothelial cell migration GO:0043536 9.74 AKT1 FGF2 VEGFA
18 positive regulation of cell division GO:0051781 9.72 FGF2 FGFR2 VEGFA
19 positive regulation of DNA-binding transcription factor activity GO:0051091 9.71 AKT1 ESR1 ESR2 PTEN
20 positive regulation of phospholipase C activity GO:0010863 9.67 ESR1 FGF2
21 replicative senescence GO:0090399 9.67 CDKN2A TP53
22 positive regulation of cardiac muscle cell proliferation GO:0060045 9.67 FGF2 FGFR2 MIR204
23 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.65 ESR1 TP53
24 negative regulation of cell size GO:0045792 9.65 AKT1 PTEN
25 paracrine signaling GO:0038001 9.62 FGF2 PGR
26 regulation of branching involved in prostate gland morphogenesis GO:0060687 9.61 ESR1 FGFR2
27 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis GO:0060527 9.6 ESR1 FGFR2
28 negative regulation of immature T cell proliferation in thymus GO:0033088 9.56 CDKN2A ERBB2
29 Ras protein signal transduction GO:0007265 9.56 CDKN2A FGF2 KRAS TP53
30 cellular response to decreased oxygen levels GO:0036294 9.52 AKT1 PTEN
31 cell migration involved in sprouting angiogenesis GO:0002042 9.5 AKT1 FGF2 VEGFA
32 prostate epithelial cord elongation GO:0060523 9.46 ESR1 FGFR2
33 positive regulation of MAP kinase activity GO:0043406 9.46 ERBB2 FGF2 KRAS VEGFA
34 cellular response to hypoxia GO:0071456 9.35 AKT1 MALAT1 PTEN TP53 VEGFA
35 positive regulation of gene expression GO:0010628 9.17 AKT1 CDKN2A ERBB2 KRAS PTEN TP53
36 nervous system development GO:0007399 10.06 AKT1 ERBB2 FGF2 PTEN VEGFA
37 positive regulation of transcription, DNA-templated GO:0045893 10.01 AKT1 CDKN2A ESR1 ESR2 FGF2 TP53

Molecular functions related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.85 AKT1 CDKN2A ESR1 PTEN TP53
2 steroid hormone receptor activity GO:0003707 9.61 ESR1 ESR2 PGR
3 identical protein binding GO:0042802 9.56 AKT1 ERBB2 ESR1 ESR2 PGR PTEN
4 nuclear receptor activity GO:0004879 9.54 ESR1 ESR2 PGR
5 nitric-oxide synthase regulator activity GO:0030235 9.48 AKT1 ESR1
6 steroid binding GO:0005496 9.43 ESR1 ESR2 PGR
7 estrogen receptor activity GO:0030284 9.4 ESR1 ESR2
8 estrogen response element binding GO:0034056 9.32 ESR1 ESR2
9 enzyme binding GO:0019899 9.17 AKT1 ESR1 ESR2 MLH1 PGR PTEN
10 protein binding GO:0005515 10.11 AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2

Sources for Endometrial Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....